Core Insights - JD Health has partnered with Yuan Da Pharmaceutical to exclusively launch the rare disease medication Anxida Amino Acid Oral Solution on its platform, aiming to improve accessibility for patients with refractory epilepsy and infantile spasms [1][2] - The collaboration emphasizes the importance of timely and continuous medication intervention for patients suffering from rare diseases, particularly in the context of drug accessibility challenges [1] - Anxida's mechanism of action as a GABA analog significantly increases GABA concentration in the brain, effectively controlling seizures, showcasing its clinical value in treating refractory epilepsy and infantile spasms [1] Company Overview - Yuan Da Pharmaceutical, with over 80 years of history, is a technology-driven pharmaceutical company that has established a comprehensive capability from research and development to commercialization in the rare disease sector [2] - The company has built a robust supply system through self-established raw material production, dedicated formulation production lines, and emergency reserve mechanisms, ensuring sustainable supply of medications like Anxida without interruptions or price increases [2] Future Outlook - JD Health plans to collaborate with innovative pharmaceutical companies like Yuan Da to accelerate the delivery of new specialty drugs to patients, enhancing the accessibility of rare disease medications [2] - The company aims to leverage its expertise in specialized disease management and pharmaceutical services to create a more supportive and trustworthy healthcare environment for patients [2]